Cardiff Oncology, Inc.
CRDFAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | $2.00(+43%) | $1.40 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | upgrade | Neutral →Buy | Sep 15, 2026 |
| William Blair | downgrade | Outperform →Market Perform | Aug 12, 2026 |
| Craig-Hallum | downgrade | Buy →Hold | Jun 3, 2026 |
| TD Cowen | downgrade | Buy →Hold | Jun 1, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 1, 2026 |
| Piper Sandler | maintain | Overweight | Feb 25, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 6, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 28, 2025 |
| Piper Sandler | maintain | Overweight | Dec 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2024 |
| Piper Sandler | maintain | Overweight | Mar 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 29, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 16, 2022 |
| Piper Sandler | maintain | Overweight | Sep 13, 2022 |
| Baird | maintain | Outperform | Aug 29, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2022 |
| HC Wainwright & Co. | maintain | Buy | Feb 28, 2022 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.13| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.14 | $-0.12 | $104.0K | $62.8K |
| May 14, 2026 | $-0.18 | $-0.13 | $41.0K | $88.6K |
| Feb 24, 2026 | $-0.11 | $-0.18 | $243.0K | $103.5K |
| Nov 6, 2025 | $-0.17 | $-0.20 | $120.0K | $103.5K |
| Jul 29, 2025 | $-0.21 | $-0.19 | $121.0K | $109.4K |
| May 8, 2025 | $-0.20 | $-0.19 | $109.0K | $89.3K |
| Feb 27, 2025 | $-0.21 | $-0.26 | $151.0K | $94.2K |
| Nov 7, 2024 | $-0.25 | $-0.27 | $165.0K | $70.0K |
News
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs.
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). “CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myelopr…
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Insider and Institutional Ownership 80.0% of
SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l.
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC